WaveMan
WaveMan · Company
ACXP · Acurx Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ACXP Acurx Pharmaceuticals (ACXP) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001736243
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
5
13F, latest reported quarter

Acurx Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Acurx Pharmaceuticals, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Scodari Joseph C
Director
BUY
2025-01-08 SECtraded 2025-01-06
24,631
$25.1K
-93.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 88.9% of the 27,708 shares held after it.
  • 5 other insiders bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Scodari Joseph C bought about $25.1K of ACXP on Jan 6, 2025, the largest insider purchase at the company since 2022; 5 other insiders bought within 30 days and 5 funds added in the latest 13F quarter.
Sailer Carl
Director
BUY
2025-01-08 SECtraded 2025-01-06
24,631
$25.1K
-93.3%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jul 27, 2022.
  • -14.2% median (-18.8% mean) 90-day return after 3 previous buys.
  • The trade is 18.0% of the 137,183 shares held after it.
  • 5 other insiders bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sailer Carl bought about $25.1K of ACXP on Jan 6, 2025, the largest insider purchase at the company since 2022; 5 other insiders bought within 30 days and 5 funds added in the latest 13F quarter.
LUCI DAVID P
President and CEO
BUY
2025-01-08 SECtraded 2025-01-06
49,261
$50.2K
-93.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jul 27, 2022.
  • -15.4% median (-15.4% mean) 90-day return after 2 previous buys.
  • The trade is 4.5% of the 1,097,458 shares held after it.
  • 5 other insiders bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO LUCI DAVID P bought about $50.2K of ACXP on Jan 6, 2025, the largest insider purchase at the company since 2022; 5 other insiders bought within 30 days and 5 funds added in the latest 13F quarter.
Donohue James J.
Director
BUY
2025-01-08 SECtraded 2025-01-06
9,852
$10.0K
-93.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 44.1% of the 22,352 shares held after it.
  • 5 other insiders bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Donohue James J. bought about $10.0K of ACXP on Jan 6, 2025, the largest insider purchase at the company since 2022; 5 other insiders bought within 30 days and 5 funds added in the latest 13F quarter.
DELUCCIA ROBERT J
Director
BUY
2025-01-08 SECtraded 2025-01-06
49,261
$50.2K
-93.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jul 27, 2022.
  • -15.4% median (-15.4% mean) 90-day return after 2 previous buys.
  • The trade is 4.9% of the 1,010,196 shares held after it.
  • 5 other insiders bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DELUCCIA ROBERT J bought about $50.2K of ACXP on Jan 6, 2025, the largest insider purchase at the company since 2022; 5 other insiders bought within 30 days and 5 funds added in the latest 13F quarter.
13 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 8 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
5 funds bought in last quarter
below 95% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.2% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 65% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ACXP

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-83.4%12M
-83%-55%-27%+2%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ACXP: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
31,099 sh
$48.2K
GEODE CAPITAL MANAGEMENT, LLC
26,411 sh
$40.9K
VANGUARD FIDUCIARY TRUST CO
16,205 sh
$25.1K
JANE STREET GROUP, LLC
15,727 sh
$24.4K
Prospect Financial Services LLC
13,785 sh
$21.4K

Congress trades in ACXP

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ACXP planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ACXP mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$32.2K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$48.2K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$5.9K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$2.0K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$289 position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 2
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 5 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ACXP financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-128.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-68.3%
TTM net income over ending balance 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-92.7%
operating income (EBIT proxy) over ending balance 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$8.1M-$14.1Mn/an/a
Net income-$8.0M-$14.1M-$14.6M-$12.1M
EPS (diluted)-5.32-17.45-1.15-1.12
Operating cash flow-$6.8M-$10.4M-$9.8M-$7.5M
SEC XBRL, fiscal years, as known on 2026-10-27

ACXP Stock Sonar score 3/7 axes

Find similar shapesCompare

ACXP ranks highest on risk and compliance (73rd percentile) and profitability (30th), and lowest on institutional and government (14th), among Pharma & Biotech peers.

Profitability
30
Inputs
  • Return on equity-128.1% · 26 pct, sector of 545
  • Return on assets-68.3% · 36 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-92.7% · 28 pct, sector of 576
Institutional and government
14
Inputs
  • Funds adding, latest quarter5 · 5 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$120K · 24 pct, sector of 133
Risk and compliance
73
Inputs
  • Short interest, % of float+2.2% · 73 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies